Mounjaro NHS eligibility: what the criteria actually mean for you

You've checked the headlines, but which phase is actually open right now?

Say you've got a BMI of 38, high blood pressure and sleep apnoea. A year ago that combination would have put Mounjaro entirely out of NHS reach. Today it still does, but not for much longer. Understanding the exact phase you're in is what matters.

From June 2025 (Cohort 1), NHS England began funding tirzepatide for adults with a BMI of 40 or above who have four or more of the five listed conditions. The NHS Mounjaro rollout is designed to expand from there. Cohort 2 activated on 23 June 2026, opening access to adults with a BMI of 35 to 39.9 who still meet the four-condition threshold. From around March 2027, Cohort 3 is expected to lower the condition requirement to three, while keeping the BMI at 40 or above. The full criteria for each cohort are set out in detail alongside the NICE recommendations.

One practical point: from 1 April 2026, GP practices can prescribe under the updated GP contract (QOF 2026/27), but participation is optional. Your surgery may not be part of the scheme yet. That's worth a direct conversation with your GP rather than an assumption either way.

NICE's recommendations chapter for tirzepatide (TA1026) sets out the full eligibility conditions and the phasing schedule.

What the five conditions mean in practice, and why BMI alone isn't enough

The five NHS qualifying conditions for Mounjaro are high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. You need four of the five, alongside the BMI requirement for your cohort. Having three, however serious they feel, currently keeps you outside Cohort 1 and 2.

BMI is calculated from height and weight, and the NHS provides a straightforward tool to check yours: the NHS BMI calculator gives an instant figure. If you're from a South Asian, Chinese, Middle Eastern, Black African or African-Caribbean background, the standard thresholds above apply 2.5 kg/m² lower, so a BMI of 37.5 may place you in the same NHS cohort as someone without that background who has a BMI of 40.

Even if all the numbers line up, a prescriber still assesses your overall health before issuing a prescription. History of medullary thyroid carcinoma or MEN2, certain gastrointestinal conditions, and pregnancy are among the reasons tirzepatide would not be appropriate. An honest clinical assessment protects you, and it's a legal requirement, not a bureaucratic hurdle.

People who are curious about whether they personally qualify for Mounjaro on the NHS often find that working through the five conditions list with a clinician is faster than reading eligibility tables alone.

If the NHS route isn't open to you right now

Waiting lists for NHS specialist weight management services (the route to Wegovy under TA875) can run to months or years in many areas. Mounjaro through the NHS is newer, and GP-practice participation is patchy. For people who don't meet the current NHS criteria, or who can't wait, a regulated private pharmacy is the alternative.

Private prescribing follows the licensed eligibility from the SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol, pre-diabetes, type 2 diabetes or obstructive sleep apnoea. The clinical bar is similar in principle to the NHS criteria, though the BMI and condition thresholds differ. Private treatment also carries a cost, what Mounjaro costs privately in the UK depends on dose and provider, and prices shifted significantly after Lilly's September 2025 list-price change.

The thing our prescribers are asked most often: does going private rule out the NHS later? It doesn't, and if you want to understand exactly how buying Mounjaro through the NHS works once you qualify in a later cohort, that's a conversation to have with your GP at that point.

If you'd like to explore whether private treatment is right for you now, starting a free consultation is the first step. A GPhC-registered prescriber reads every submission personally (your answers don't go to a triage algorithm) and reviews are completed the same day.

A note on supply, pen storage and transferring between routes

Whether you're prescribed Mounjaro through the NHS or privately, the pen lives in the fridge door between your Monday doses, kept between 2 and 8°C. The Patient Information Leaflet (not your memory of an online article) is the authority on the limited room-temperature window if you're travelling or your fridge is off. Don't guess; check the leaflet.

If you're currently on Mounjaro through a private service and your GP practice joins the NHS scheme, a transfer is possible in principle but requires a new clinical assessment under NHS criteria. Prescribers treat that as a fresh consultation, not a rubber stamp. Similarly, if you've been on a dose other than the 2.5mg starter, evidence of your current treatment is standard practice before any continuation or increase.

For questions about the NHS rollout specific to Scotland, Wales or Northern Ireland, criteria differ from the England thresholds above. Who qualifies for Mounjaro on the NHS covers the devolved-nation position in more detail. The NHS England weight management injections guidance remains the primary published source for the England rollout.